News | March 10, 2009

Study Shows PAD Detection to Increase, Treatment Market to Grow

March 10, 2009 – As early detection increases for peripheral arterial disease (PAD) and more patients seek treatment, the U.S. market for peripheral vascular treatment will grow to an estimated $4.7 billion by 2015, according to iData Research, an international medical device & dental market research firm.

Currently, of the estimated 10 million people in the U.S. who suffer from lower limb Peripheral Arterial Disease (PAD), 80 percent go undiagnosed, the study revealed.

PAD is the formation of plaque in arterial blood vessels of the outer circulatory system that causes damage to the arterial wall, which in turn increases the risk of stroke. In 2008, over 4 million individuals in the U.S. had symptoms indicative of PAD, such as persistent leg cramping, numbness, fatigue and severe pain.

"Of people aged 50 to 69 with a history of smoking or diabetes, approximately 30 percent will manifest PAD," says Kamran Zamanian, Ph.D., CEO of iData Research, "This will drive sales for PAD treatment devices, particularly for devices such as stents and stent-grafts, and complementary and alternative products, like embolic protection and atherectomy devices."

In 2008, the largest segment in the U.S. market for peripheral vascular devices was for stents, which represented 28.7 percent of the overall treatment market. The stent market will grow at double digit rates through 2015, led by an increase in early diagnoses. The U.S. government and the medical community have taken an active role in improving awareness of PAD among physicians and the general population.

For more information: www.idataresearch.net

Related Content

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | January 25, 2019
January 25, 2019 — Profusa announced promising...
BEST-CLI Trial Examining Critical Limb Ischemia Treatment Options Nears Enrollment Goal
News | Peripheral Artery Disease (PAD) | January 23, 2019
A new report in the Journal of Vascular Surgery chronicles a multi-site randomized controlled trial comparing treatment...
FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...
New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018
A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...
Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
Overlay Init